FDA GMP changes would require more extensive investigations of out-of-spec lab results.
FDA GMP PROPOSAL WOULD REQUIRE WRITTEN PROCEDURES FOR OUT-OF-SPEC INVESTIGATIONS as one of several proposed changes to the current Good Manufacturing Practices regulations for finished pharmaceuticals, according to a May 3 Federal Register notice. The comment period for the proposed rules runs until Aug. 1. FDA proposes that Section 211.192(b) be amended to require written procedures for investigation and determination of the cause of any failure, discrepancy or out-of-specification laboratory result.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth